Tags

Type your tag names separated by a space and hit enter

Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.
Acta Derm Venereol. 2021 Mar 23; 101(3):adv00420.AD

Abstract

Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen non-collagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, follow-ed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

Links

Publisher Full Text

Authors+Show Affiliations

Holtsche MM
Department of Dermatology, University of Lubeck, DE-23522 Lubeck, Germany.
van Beek N
No affiliation info available
Hashimoto T
No affiliation info available
Di Zenzo G
No affiliation info available
Zillikens D
No affiliation info available
Prost-Squarcioni C
No affiliation info available
Titeux M
No affiliation info available
Hovnanian A
No affiliation info available
Schmidt E
No affiliation info available
Goletz S
No affiliation info available

MeSH

AutoantibodiesCollagen Type VIIEpidermolysis Bullosa AcquisitaFluorescent Antibody Technique, IndirectGermanyHumansJapan

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

33686442

Citation

Holtsche, Maike M., et al. "Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity." Acta Dermato-venereologica, vol. 101, no. 3, 2021, pp. adv00420.
Holtsche MM, van Beek N, Hashimoto T, et al. Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity. Acta Derm Venereol. 2021;101(3):adv00420.
Holtsche, M. M., van Beek, N., Hashimoto, T., Di Zenzo, G., Zillikens, D., Prost-Squarcioni, C., Titeux, M., Hovnanian, A., Schmidt, E., & Goletz, S. (2021). Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity. Acta Dermato-venereologica, 101(3), adv00420. https://doi.org/10.2340/00015555-3774
Holtsche MM, et al. Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity. Acta Derm Venereol. 2021 Mar 23;101(3):adv00420. PubMed PMID: 33686442.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity. AU - Holtsche,Maike M, AU - van Beek,Nina, AU - Hashimoto,Takashi, AU - Di Zenzo,Giovanni, AU - Zillikens,Detlef, AU - Prost-Squarcioni,Catherine, AU - Titeux,Matthias, AU - Hovnanian,Alain, AU - Schmidt,Enno, AU - Goletz,Stephanie, Y1 - 2021/03/23/ PY - 2021/3/10/pubmed PY - 2021/6/24/medline PY - 2021/3/9/entrez KW - BIOCHIP KW - autoantibody KW - enzyme-linked immunoassay KW - immunoblot KW - type VII collagen KW - epidermolysis bullosa acquisita SP - adv00420 EP - adv00420 JF - Acta dermato-venereologica JO - Acta Derm Venereol VL - 101 IS - 3 N2 - Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen non-collagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, follow-ed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%). SN - 1651-2057 UR - https://www.unboundmedicine.com/medline/citation/33686442/Diagnosis_of_Epidermolysis_Bullosa_Acquisita:_Multicentre_Comparison_of_Different_Assays_for_Serum_Anti_type_VII_Collagen_Reactivity_ L2 - https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3774 DB - PRIME DP - Unbound Medicine ER -

Related Citations

More